Infectious diseasesHeme detoxification and antimalarial drugs – Known mechanisms and future prospects
Section editors:
Gary Woodnutt – CovX, San Diego, USA
Paul-Henri Lambert – Centre of Vaccinology, University of Geneva, Switzerland
Introduction
Malaria is the most lethal parasitic disease that kills more than one million individuals each year. Whereas malaria infection begins with the invasion of hepatocytes by the Plasmodium sporozoites inoculated by an infected mosquito, clinical symptoms of malaria, which includes high fever, chills and anemia, are due to the subsequent infection and rapid multiplication of the parasite inside the red blood cells (RBCs). To sustain its rapid pace of development, the parasite cannibalizes hemoglobin (Hb), which represents 90% of the total protein present inside an RBC [1]; approximately 75% of which is degraded during the erythrocytic stage of development [2]. Degradation of hemoglobin releases heme, which is effectively neutralized by the parasite, primarily by its conversion into an insoluble crystalline material called hemozoin, by utilizing a mechanism that is not fully understood.
Section snippets
Mechanism of hemoglobin transport
The process starts with the formation of a double membrane cytostome, an invagination in the plasma and parasitophorous membrane of the parasite, which intakes host cytoplasm (primarily containing Hb) in a pinocytic fashion and subsequently buds off as a transport vesicle (Tv) (Fig. 1). This Hb-laden Tv undertakes a retrograde trip to the food vacuole (Fv), an oxygen-rich, lysosome-like organelle in the parasite to which it fuses and delivers its contents (Fig. 1). Inside the Fv, several
Heme detoxification is a unique drug target
Several ancient antimalarials known to traditional healers as well as some of the most potent drugs developed during the pre-genomic era, exert their antimalarial activity by blocking heme detoxification. In fact, prevention of heme detoxification is the most widely used strategy for controlling malaria (Table 1). Chloroquine, the most widely used antimalarial in history, binds to heme [6, 7] with a 1:2 stoichiometry [8] and prevents its detoxification, leading to heme toxicity and death of the
Known mechanisms of heme detoxification
In the past two decades, several mechanisms for heme detoxification have been identified in vitro, primarily by utilizing parasite extracts from human and rodent parasites. Based on outcomes, all the known mechanisms can be broadly classified into two major types. One involves accumulation of heme by its dimerzation and stacking into a nontoxic crystalline product called hemozoin (Hz) (Fig. 2) whereas the other suggests degradation of heme by glutathione (GSH) and hydrogen peroxide. Although,
Chemical structure of Hz
In a parasite-infected RBC, Hz is visible under the microscope as a dark pigmented body and was one of the key factors in the discovery of the parasite. The chemical structure of Hz has been deciphered utilizing several spectroscopic techniques [11, 12]. The Hz crystal is composed of unit cells of ferriprotoporphyrin (FP) dimers (also known as Fe1–O41 dimers) coordinated by reciprocal iron to side chain carboxylate bonds (Fig. 3). These individual head to tail dimers form a hydrogen bond
How is Hz made?
In the past 15 years, several processes that lead to Hz formation under in vitro conditions have been identified. Hz formation has been shown to be possible utilizing parasite proteins, lipid extracts, preformed Hz crystals, along with theories that its formation is chemically driven, independent of any parasite or host factors. A summary of each of the known processes along with their limitations is depicted in Table 2.
Hydrogen peroxide and glutathione mediated heme degradation
Along with Hz formation, possibility of a hydrogen peroxide-mediated decomposition of heme in the food vacuole has also been demonstrated. Under acidic conditions in vitro, hydrogen peroxide has been shown to degrade heme [24, 31]. Likewise, a cytosolic, glutathione-mediated model of heme degradation has also been proposed. This model suggests that heme that is not converted into Hz, escapes from the Fv to the parasite cytosol where it is degraded by glutathione (GSH) [26]. Although, parasite
Heme targeted drug discovery
Whereas several antimalarials from the pre-genomic era that fortuitously target this pathway are already in the market, opportunities for developing new drugs that inhibit this pathway have not been fully explored. With the advent of high throughput screening (HTS), attempts are now focused on screening compound libraries for identification of new inhibitors of this pathway. These attempts have been greatly facilitated with the miniaturization of assays that until recently were primarily
Conclusions
Protective mechanisms employed by the parasite to defend itself from the toxic effects of heme are poorly understood. One of the major reasons behind our limited understanding is the inability to study these mechanisms in a live parasite, which has made their in vivo validation a major challenge. Nonetheless, the available information regarding these mechanisms has provided vital clues about one of the most novel strategies employed by the parasite for its development and survival inside the
Acknowledgements
This work was supported by a JHU-VBI Infectious disease research partnership and the university research funds to D.R. We thank June Mullins for technical support and Wandy Beatty for the electron micrograph of the parasite. The views expressed herein are of the authors and do not represent the official position of the US Food and Drug Administration.
References (37)
Heme-artemisinin adducts are crucial mediators of the ability of artemisinin to inhibit heme polymerization
Chem. Biol.
(2002)Interference with heme binding to histidine-rich protein-2 as an antimalarial strategy
Chem. Biol.
(2002)Trans expression of a Plasmodium falciparum histidine-rich protein II (HRPII) reveals sorting of soluble proteins in the periphery of the host erythrocyte and disrupts transport to the malarial food vacuole
J. Biol. Chem.
(2002)Involvement of lipids in ferriprotoporphyrin IX polymerization in malaria
Biochim. Biophys. Acta
(1999)Hemozoin formation in malaria: a two-step process involving histidine-rich proteins and lipids
Biochem. Biophys. Res. Commun.
(2003)Inhibition of glutathione-dependent degradation of heme by chloroquine and amodiaquine as a possible basis for their antimalarial mode of action
Biochem. Pharmacol.
(1998)Ferriprotoporphyrin IX, phospholipids, and the antimalarial actions of quinoline drugs
Life Sci.
(2004)Physico-chemical aspects of hemozoin (malaria pigment) structure and formation
J. Inorg. Biochem.
(2002)Histidine-rich protein 2 of the malaria parasite, Plasmodium falciparum, is involved in detoxification of the by-products of haemoglobin degradation
Mol. Biochem. Parasitol.
(2001)Haemoproteus and Schistosoma synthesize heme polymers similar to Plasmodium hemozoin and beta-hematin
Mol. Biochem. Parasitol.
(2001)
Haemozoin in Schistosoma mansoni
Mol. Biochem. Parasitol.
Hemozoin formation in Echinostoma trivolvis rediae
Int. J. Parasitol.
Quinoline anti-malarial drugs inhibit spontaneous formation of beta-haematin (malaria pigment)
FEBS Lett.
Hemoglobin metabolism in the malaria parasite Plasmodium falciparum
Annu. Rev. Microbiol.
Hemoglobin degradation in the malaria parasite Plasmodium falciparum: an ordered process in a unique organelle
Proc. Natl. Acad. Sci. U S A
Antimalarial drugs: current status and new developments
Expert Opin. Invest. Drugs
Antimalarial activities of novel synthetic cysteine protease inhibitors
Antimicrob. Agents Chemother.
Cited by (28)
Antiplasmodial activity: The first proof of inhibition of heme crystallization by marine isonitriles
2015, European Journal of Medicinal ChemistryCitation Excerpt :The discovery that β-hematin (the synthetic equivalent of hemozoin) may be synthesized in a laboratory has initiated a debate as to whether the crystallization in vivo is a spontaneous chemical or biological facilitated process, as many of these in vitro methods are conducted in supraphysiological conditions, such as high temperature (60 °C) in the Egan's β-hematin inhibitory assay (EBHIA) and pyridine hemichrome inhibition of β-hematin (Phi-β) or lengthy incubation times (18–24 h) in both the heme-crystallization inhibitory activity (HPIA) and the β-hematin inhibitory activity (BHIA) assays. However, the consensus view is that the sequestration of heme into hemozoin in vivo occurs by a multifarious mechanism, where lipids may play a major role in mediating the crystallization of heme to hemozoin [30,31]. A summary of known mechanisms of heme-crystallization and valid criticisms of each mechanism is presented in Table 1.
Konsep Penghibridan 4-Aminokuinolina sebagai Alternatif Agen Antiplasmodium
2022, Sains MalaysianaThe Target Determination and the Mechanism of Action of Chiral-Antimalarial Drugs: A Docking Approach
2021, Journal of Computational Biophysics and ChemistryEvidence for in vitro and in vivo activity of the antimalarial pyronaridine against schistosoma
2021, PLoS Neglected Tropical Diseases